{"id":"oxervate-0-002","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Punctate keratitis"},{"rate":null,"effect":"Foreign body sensation"}]},"_chembl":{"chemblId":"CHEMBL4297852","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nerve growth factor is a naturally occurring protein that stimulates the growth and survival of nerve cells. In neurotrophic keratopathy, corneal nerves are damaged or absent, leading to loss of protective sensation and corneal ulceration. By supplying exogenous NGF topically, OXERVATE restores corneal innervation and promotes epithelial healing through neurotrophic signaling pathways.","oneSentence":"OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:11.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)"}]},"trialDetails":[{"nctId":"NCT05552261","phase":"","title":"DEFENDO Long Term Follow-up Study in Stage 1 NK Patients","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2023-02-01","conditions":"Neurotrophic Keratitis","enrollment":24},{"nctId":"NCT04485546","phase":"PHASE4","title":"Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2020-09-09","conditions":"Neurotrophic Keratitis","enrollment":37},{"nctId":"NCT06411145","phase":"PHASE4","title":"Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis","status":"WITHDRAWN","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-04-26","conditions":"Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer","enrollment":""},{"nctId":"NCT05700864","phase":"PHASE1","title":"NGF Treatment for Patients With Neuropathic Corneal Pain","status":"WITHDRAWN","sponsor":"Tufts Medical Center","startDate":"2022-11-01","conditions":"Corneal Disease, Neuropathy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cenegermin-bkbj"],"phase":"marketed","status":"active","brandName":"OXERVATE® 0.002%","genericName":"OXERVATE® 0.002%","companyName":"Dompé Farmaceutici S.p.A","companyId":"domp-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy. Used for Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}